GBT Reports Fourth Quarter and Full Year 2021 Financial Results
23 févr. 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year Executed on key growth opportunities highlighted...
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
16 févr. 2022 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial...
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
16 févr. 2022 06h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the European Commission (EC) has granted Marketing Authorization...
GBT Announces New Employment Inducement Grants
03 févr. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2022, the compensation committee of GBT’s board...
Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease
27 janv. 2022 03h00 HE
|
Global Blood Therapeutics, Inc.
LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has awarded a positive scientific...
Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States
10 janv. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced Oxbryta® (voxelotor) tablets for oral suspension, a new...
GBT Announces New Employment Inducement Grants
06 janv. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2022, the compensation committee of GBT’s board...
GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare...
U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease
17 déc. 2021 14h05 HE
|
Global Blood Therapeutics, Inc.
New dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the root cause of red blood cell sickling SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE)...
GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older
17 déc. 2021 10h33 HE
|
Global Blood Therapeutics, Inc.
European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS)...